Ozempic Linked to Higher Employment in Denmark
A NYU Abu Dhabi study of Danish population records links diabetes and weight-loss drug treatment to changes in work and earnings.
Updated on Nov. 2, 2026 in Weight Loss
Live Poll
Should governments subsidise weight-loss medications like Wegovy for everyday patients?
Researchers at NYU Abu Dhabi found that Ozempic treatment increased the probability of employment by 4.1 percentage points and working hours by 19.5 hours per quarter among patients receiving subsidised diabetes treatment in Denmark. The findings draw on Danish population records from 2018 to 2024.
Why it matters
The results suggest that treating obesity-related conditions could affect labour market participation as well as health outcomes. Researchers said the additional income tax revenue from increased labour income could help offset spending on subsidised diabetes treatment.
Danish registry data from 2018 to 2024 show Ozempic treatment raised employment probability by 4.1 percentage points and working hours by 19.5 per quarter for subsidised patients, while Wegovy showed no significant employment gain among out-of-pocket users. Researchers have not yet determined whether these labour effects are sustained over time.
The players
NYU Abu Dhabi
A research university whose researchers conducted the study comparing employment outcomes of patients using Ozempic and Wegovy.
Centre for Economic Policy Research
A London-based network of economists that published the study as a discussion paper.
Abu Dhabi Department of Health
The health authority for the emirate of Abu Dhabi, currently collaborating on ongoing research into the Thiqa obesity programme.
The details
The team compared changes in employment, working hours and earnings before and after individuals began treatment, using statistical methods to separate treatment effects from broader labour-market shifts. In Denmark, Ozempic for diabetes is subsidised, while patients using Wegovy for weight management pay the full cost themselves. The study was released as a discussion paper by the Centre for Economic Policy Research.
Timeline
2018 to 2024: Danish population records analysed for employment and earnings changes.
November 2, 2026: Article published on the study findings.
Roadmap
The findings extend a growing body of research on GLP-1 drugs such as Ozempic beyond glucose control and weight, into labour-market outcomes. Denmark's decision to subsidise diabetes treatment while leaving weight-management use out of pocket creates a natural comparison that this study uses to separate cost-sharing effects from the drugs themselves.
For people with diabetes in Denmark, subsidised Ozempic treatment is linked to higher employment and working hours, a finding that may matter to patients weighing treatment decisions alongside work. Readers paying for weight-management drugs out of pocket should note that the study found no significant employment gain for that group.
The takeaway
Treatment access and cost-sharing may shape not only health outcomes but also employment and income, so policy decisions about subsidies can carry economic effects beyond healthcare budgets. Patients considering these drugs should discuss both health and work-related considerations with their clinicians.
Further reading
For broader context on drug treatments for obesity and related conditions, explore the Weight Loss section.
Source note: This article includes information reported by Khaleej Times.
Live Poll
Should governments subsidise weight-loss medications like Wegovy for everyday patients?
